낙동강 수계에서의 고지혈증 치료제 검출 특성 = original article : Detection Characteristics of Blood Lipid Lower Agents (BLLAs) in Nakdong River Basin

다국어 초록 (Multilingual Abstract)

The aims of this study were to investigate and confirm the occurrence and distribution patterns of blood lipid lower agents (BLLAs) in Nakdong river basin (mainstream and its tributaries). 4 (atorvastatin, lovastatin, mevastatin and simvastatin) out of 5 statins and 2 (clofibric acid and zemfibrozil) out of 3 fibrates were detected in 29 sampling sites and simvastatin (>50%) was predominant compound followed by atorvastatin, lovastatin and clofibric acid. The total concentration levels of BLLAs on April, August and November 2009 in surface water samples ranged from ND∼25.7 ng/L, ND∼18.8 and ND to 38.8 ng/L, respectively. The highest concentration level of BLLAs in the mainstream and tributaries in Nakdong river were Goryeong and Jincheon-cheon, respectively. The sewage treatment plants (STPs) along the river affect the BLLAs levels in river and the BLLAs levels decreased with downstream because of dilution effects.

참고문헌 (Reference)

1 서창동, "낙동강 수계에서의 인공 사향물질 검출 특성" 대한환경공학회 32 (32): 615-624, 2010

2 손희종, "낙동강 수계에서의 과불화 화합물(PFCs) 검출 특성" 대한환경공학회 35 (35): 84-93, 2013

3 Dorne, J. L. C., "Trends in human risk assessment of pharmaceuticals" 387 : 1167-1172, 2007

4 Mimeault, C., "The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the goldfish, Carassius auratus" 73 : 44-54, 2005

5 Stumpf, M., "Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil" 225 : 135-141, 1999

6 손희종, "On-Line SPE-LC/MSD 시스템을 이용한 수중의 과불화 화합물(PFCs) 분석" 대한환경공학회 35 (35): 75-83, 2013

7 Moldovan, Z., "Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania" 64 : 1808-1817, 2006

8 Halling-Sorensen, B., "Occurrence, fate and effects of pharmaceutical substances in the environment―a review" 36 (36): 357-393, 1998

9 Ternes, T, A., "Occurrence of drug in German sewage treatment plants and rivers" 32 (32): 3245-3260, 1998

10 Bendz, D., "Occurrence and fate of pharmaceutically active compounds in the environment, a case study : Höje River in Sweden" 122 : 195-204, 2005

11 Mompelat, S., "Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water" 35 : 803-814, 2009

12 Hernando, M. D., "LC-MS analysis and environmental risk of lipid regulators" 387 (387): 1269-1285, 2007

13 Yamamoto, H., "Initial ecological risk assessment of eight selected human pharmaceuticals in Japan" 14 : 177-193, 2007

14 Pal, A., "Impacts of emerging organic contaminants on freshwater resources : review of recent occurrences, sources, fate and effects" 408 : 6062-6069, 2010

15 Westerhoff, P., "Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes" 39 : 6649-6663, 2005

16 Fent, K., "Ecotoxicology of human pharmaceuticals" 76 : 122-159, 2006

17 Farré, M., "Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry : methods and preliminary results including toxicity studies with Vibrio fischeri" 938 : 187-197, 2001

18 Martín, J., "Comparison of different extraction methods for the determination of statin drugs in wastewater and river water by HPLC/QTOF-MS" 85 : 607-615, 2011

19 손희종, "Caffeine과 Carbamazepine: 낙동강 수계에서의 검출 및 정수처리 공정에서의 거동" 한국환경과학회 21 (21): 837-843, 2012